Biologics for Psoriasis Treatment

							            .
Psoriasis2007 jp
    Shima Mie




Biologics for
Psoriasis
Treatment

                                    ââÅ@é“
                               ţ




                               Associate Professor of Medicine
                                                (Dermatology),
                                          Dalhousie University
                                    Richard G.B.Langley, MD
                                                   ìØéûíñÛdžÇË



ÉzÉeÉãéuñÄÉXÉyÉCÉìë ∫ A âÔèÍ
                                         Richard G.B. Langley, MD
                                   Associate Professor of Medicine (Dermatology),
                                                            Dalhousie University




Profile
     July, 2005 –                  Associate Professor of Medicine (Dermatology), Dalhousie University

     May, 2000 –                   Active Staff, QEII Health Sciences Centre

     May, 2000 – June, 2005        Assistant Professor of Medicine (Dermatology), Dalhousie University

     July, 1999 – July, 2000       Assistant Dermatologist, Active Staff, Massachusetts General Hospital

     July, 1997 – July, 1999       Assistant in Dermatology, Active Staff, Massachusetts General Hospital

     November, 1997 – July, 2000   Chief, Dermatology Clinical Investigations Unit, Massachusetts General Hospital,
                                   Harvard Medical School

     September, 1997 – May, 2001   Instructor in Dermatology, Harvard Medical School




Abstract
Psoriasis is a chronic immune mediated skin disease principally mediated by T cells, dendritic cells
and inflammatory cytokines. New research into possible treatment options has been inspired by
increased understanding of the pathophysiology of psoriasis and advances in immunology and
molecular biology permitting the development of targeted, highly active biologic agents. Emerging
immunotherapeutic agents (fusion proteins, recombinant cytokines, fusion toxins, or antibodies) target
T-cells or cytokines responsible for plaque formation that is characteristic of psoriasis. Alefacept,
Efalizumab, Etanercept, and in certain countries infliximab, have been recently approved for the
treatment of psoriasis. Adalimumab has recently completed phase III clinical trials in psoriasis. This
session will review the essential concepts in the immunopathogenesis of psoriasis and describe the
modes of action of the different biologic therapies, with practical considerations for therapy.



        éÂÇ… ñEÅA èÛç◊ âä è«ê´ ÉT ÉgÉJÉC Ç™ Ç∑ ñùê´ ìI Ç»ñ∆
  䣷ù ÇÕ  Tç◊ é˜     ñEÅA       ÉC     Éì âÓç› ÇÈ              àŸèÌ Ç î∫ǧîÁïÜéæä≥
                                                           âuånÇÃ
 džÇÈ Å@ 䣷ù ÇÃ ë‘ ê∂
Ç≈   ÅBãflîNÅA  ïa     óùäwÇ… ÇÈ
                           ä÷Ç∑ óùâ Çà ⪠ǻÇÁ Ç… âuäwÇ‚ï™
                                     ê[      Ç— ñ∆        éqê∂     êi    ÇÊ êVÇΩ
                                                              ï®äwÇÃ ï‡ Ç… ÇË
       ñ@ ä÷Ç∑ å§ãÜÇ™ Ç›ÅA
Ç»é° ó√ Ç… ÇÈ       êi   Ç´ÇÌÇflǃçÇÇ¢äà ê´ Ç éùǬ ï®äwìI êª ç‹ Çà î≠Ç™ Ç∆
                                                 ê∂             äJ             ÅB êVǵ
                                                                     â¬î\ ǻǡÇΩ Å@ Ç¢
ñ∆    ñ@ Ç… óZçá É^ÉìÉpÉN ëgÇ›ä∑
  âuó√ ñÚ ÇÕ            ÅA      ǶÉT ÉgÉJÉC óZçá ì≈ëf ÅA
                                    ÉC     ÉìÅA                 džÇË Ç± ÇÃ ç‹ ä£·ù
                                                       çRëÃǻǫǙ ÅA ÇÍÇÁ ñÚ ÇÕ
 ì¡    džÇÈ
ÇÃ í• Ç≈         å`
           îÁê] ÇÃ ê¨ Ç…
                       ä÷ó^Ç∑ Tç◊
                            ÇÈ ñEÇ‚ÉT ÉgÉJÉC Ç ïW Ç∆ ǃǢÇÈ Å@ ÇÎêVÇΩ
                                     ÉC     Éì   ìI ǵ     ÅBêÊÇ≤   ǻ䣷ù é° ó√
  Ç∆ ǃAle fa c e p t ÅA lizu m a b ÅA a n e r c e p t Ç™ îF Ç≥ àÍ ïî Çà Ç≈ In flixim a b ÇÃ
ñÚ Çµ                  Efa           Et                 è≥    ÇÍÅA     çë ÇÕ                           Ç»
                                                                                           égópLJâ¬î\ Ç∆
   ÅB Ç‹ÇΩ Ad             Ǭ ǃÇÕ ä£·ù Ç ëŒ
Ç¡ÇΩ Å@ ÅA a lim u m a b Ç… Ç¢  ÅA         è€Ç∆ ÇΩ
                                              ǵ ëÊÅ@ ó’ è∞ å±Ç™ Ç¢ç≈
                                                    ëä     éé  Ç¬        óπ ÇΩ DZ
                                                                     ãfläÆ Çµ Ç∆ ÇÎÇ≈
    ÅBñ{ÉZ      ÇÕ ä£·ù ñ∆
džÇÈ Å@ É~Éi Å[Ç≈ ÅA Çà âuäwìI ïa àˆ ÇÃ
                                      äÓñ{äTîOÇ… ǢǃäTê‡Ç∑ Ç∆ Ç‡Ç…é¿ ín à„ ó√ Ç® ÇÈ
                                               Ǭ         ÇÈ Ç∆   ÅA          Ç… ÇØ
                                              ǃèqÇ◊ÇΩÇ¢ÅB
ñ‚ëËì_LJçló∂ǵǻǙÇÁäeê∂ï®äwìIêªç‹ÇÃçÏópã@èòDžǬǢ